larrylim11的个人主页 - 老虎社区

larrylim11

larrylim11

暂无个人介绍

IP属地：未知

2关注

1粉丝

0主题

0勋章

2021-12-23

//@iNights: NiceWhoa

Moderna Is Dipping: What's Next?

2021-12-23

Yea..

2021-12-23

Wow..

Apple Stock: Will The Apple Car Be The Ultimate ‘Tesla Killer?’

2021-12-23

Keep going!

抱歉，原内容已删除

2021-12-23

Market will go back up!

2021-12-23

Good stuff

Why Paychex Shares Are Making New All-Time Highs Today

2021-12-18

Good stuff

2021-12-17

Good stuff

CDC Advisers Recommend Pfizer, Moderna Covid-19 Vaccines Over J&J’s

2021-12-17

Good stuff!

抱歉，原内容已删除

2021-11-06

Whee!

@小虎活动:[Halloween Game] Trade or Treat!

2021-11-04

Yes!

@小虎活动:[Halloween Game] Trade or Treat!

2021-11-03

Woo hoo!

@小虎活动:[Halloween Game] Trade or Treat!

2021-07-14

Good stuff

抱歉，原内容已删除

2021-07-08

Oh no..

抱歉，原内容已删除

2021-06-29

Good stuff!

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"4087961992375920","uuid":"4087961992375920","gmtCreate":1624859373762,"gmtModify":1624976947105,"name":"larrylim11","pinyin":"larrylim11","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/b349c02fde492311c83f02b5acc9f8dd","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":2,"tweetSize":15,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.11.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.10.25","exceedPercentage":"93.18%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.05.14","exceedPercentage":"93.68%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.03.06","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":13,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":691413731,"gmtCreate":1640226836214,"gmtModify":1640226836302,"author":{"id":"4087961992375920","authorId":"4087961992375920","name":"larrylim11","avatar":"https://static.tigerbbs.com/b349c02fde492311c83f02b5acc9f8dd","crmLevel":13,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087961992375920","authorIdStr":"4087961992375920"},"themes":[],"htmlText":"//<a href=\"https://laohu8.com/U/3576822652797861\">@iNights</a>: NiceWhoa","listText":"//<a href=\"https://laohu8.com/U/3576822652797861\">@iNights</a>: NiceWhoa","text":"//@iNights: NiceWhoa","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691413731","repostId":"1181809495","repostType":4,"repost":{"id":"1181809495","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640225885,"share":"https://www.laohu8.com/m/news/1181809495?lang=&edition=full","pubTime":"2021-12-23 10:18","market":"us","language":"en","title":"Moderna Is Dipping: What's Next?","url":"https://stock-news.laohu8.com/highlight/detail?id=1181809495","media":"Benzinga","summary":"Moderna Inc shares are trading lower Wednesday and are falling toward a support level.\nThe stock was","content":"<p><b>Moderna Inc</b>&nbsp;shares are trading lower Wednesday and are falling toward a support level.</p>\n<p>The stock was trending on social media sites throughout the day after the stock saw some movement.</p>\n<p>Moderna was down 6.26% at $251.36 at market close Wednesday.</p>\n<p><b>Moderna Daily Chart Analysis</b></p>\n<ul>\n <li>Shares dipped toward support in what traders call an ascending triangle pattern. Shares could see another bounce off the higher low support at some point in the future. Resistance is shown to be near the $460 level.</li>\n <li>The stock trades below the 50-day moving average (green) but above the 200-day moving average (blue). This indicates the stock is likely in a consolidation period, and the 50-day moving average may act as resistance while the 200-day moving average may hold as support.</li>\n <li>The Relative Strength Index (RSI) has been creeping lower the past few days and sits at 41. This shows that sellers are prevailing in the stock and are slightly overpowering buyers.</li>\n</ul>\n<p><img src=\"https://static.tigerbbs.com/62170d670dca987c7cbc558dd6666d0c\" tg-width=\"2400\" tg-height=\"1233\" width=\"100%\" height=\"auto\"></p>\n<p><b>What’s Next For Moderna?</b></p>\n<p>Moderna has seen a dip the past few days and is falling back toward the higher low trendline. If this area can see a bounce again the price may start to head toward resistance once again. Bulls are looking for higher lows to continue to form for the stock to keep the bullish trend. Bears are looking to see the stock fall below this trendline and for the price to start moving with lower highs.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Is Dipping: What's Next?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Is Dipping: What's Next?\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-12-23 10:18</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Moderna Inc</b>&nbsp;shares are trading lower Wednesday and are falling toward a support level.</p>\n<p>The stock was trending on social media sites throughout the day after the stock saw some movement.</p>\n<p>Moderna was down 6.26% at $251.36 at market close Wednesday.</p>\n<p><b>Moderna Daily Chart Analysis</b></p>\n<ul>\n <li>Shares dipped toward support in what traders call an ascending triangle pattern. Shares could see another bounce off the higher low support at some point in the future. Resistance is shown to be near the $460 level.</li>\n <li>The stock trades below the 50-day moving average (green) but above the 200-day moving average (blue). This indicates the stock is likely in a consolidation period, and the 50-day moving average may act as resistance while the 200-day moving average may hold as support.</li>\n <li>The Relative Strength Index (RSI) has been creeping lower the past few days and sits at 41. This shows that sellers are prevailing in the stock and are slightly overpowering buyers.</li>\n</ul>\n<p><img src=\"https://static.tigerbbs.com/62170d670dca987c7cbc558dd6666d0c\" tg-width=\"2400\" tg-height=\"1233\" width=\"100%\" height=\"auto\"></p>\n<p><b>What’s Next For Moderna?</b></p>\n<p>Moderna has seen a dip the past few days and is falling back toward the higher low trendline. If this area can see a bounce again the price may start to head toward resistance once again. Bulls are looking for higher lows to continue to form for the stock to keep the bullish trend. Bears are looking to see the stock fall below this trendline and for the price to start moving with lower highs.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1181809495","content_text":"Moderna Inc shares are trading lower Wednesday and are falling toward a support level.\nThe stock was trending on social media sites throughout the day after the stock saw some movement.\nModerna was down 6.26% at $251.36 at market close Wednesday.\nModerna Daily Chart Analysis\n\nShares dipped toward support in what traders call an ascending triangle pattern. Shares could see another bounce off the higher low support at some point in the future. Resistance is shown to be near the $460 level.\nThe stock trades below the 50-day moving average (green) but above the 200-day moving average (blue). This indicates the stock is likely in a consolidation period, and the 50-day moving average may act as resistance while the 200-day moving average may hold as support.\nThe Relative Strength Index (RSI) has been creeping lower the past few days and sits at 41. This shows that sellers are prevailing in the stock and are slightly overpowering buyers.\n\n\nWhat’s Next For Moderna?\nModerna has seen a dip the past few days and is falling back toward the higher low trendline. If this area can see a bounce again the price may start to head toward resistance once again. Bulls are looking for higher lows to continue to form for the stock to keep the bullish trend. Bears are looking to see the stock fall below this trendline and for the price to start moving with lower highs.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":1686,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691413302,"gmtCreate":1640226771801,"gmtModify":1640226771801,"author":{"id":"4087961992375920","authorId":"4087961992375920","name":"larrylim11","avatar":"https://static.tigerbbs.com/b349c02fde492311c83f02b5acc9f8dd","crmLevel":13,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087961992375920","authorIdStr":"4087961992375920"},"themes":[],"htmlText":"Yea..","listText":"Yea..","text":"Yea..","images":[{"img":"https://static.tigerbbs.com/e20070159fdd392e5a013b6c48806820","width":"1080","height":"1309"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691413302","isVote":1,"tweetType":1,"viewCount":1353,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":691419155,"gmtCreate":1640226681816,"gmtModify":1640226681874,"author":{"id":"4087961992375920","authorId":"4087961992375920","name":"larrylim11","avatar":"https://static.tigerbbs.com/b349c02fde492311c83f02b5acc9f8dd","crmLevel":13,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087961992375920","authorIdStr":"4087961992375920"},"themes":[],"htmlText":"Wow..","listText":"Wow..","text":"Wow..","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691419155","repostId":"1141555850","repostType":4,"repost":{"id":"1141555850","kind":"news","pubTimestamp":1640226334,"share":"https://www.laohu8.com/m/news/1141555850?lang=&edition=full","pubTime":"2021-12-23 10:25","market":"us","language":"en","title":"Apple Stock: Will The Apple Car Be The Ultimate ‘Tesla Killer?’","url":"https://stock-news.laohu8.com/highlight/detail?id=1141555850","media":"TheStreet","summary":"Apple’s EV catalyst may help to boost returns in the long run. But in the near-term, it’s likely alr","content":"<p>Apple’s EV catalyst may help to boost returns in the long run. But in the near-term, it’s likely already priced into AAPL stock.</p>\n<p>Last week, we broke down Apple stock&nbsp;and its metaverse catalyst. Specifically, why the tech giant’s move into AR (augmented reality) and VR (virtual reality) hardware may give shares&nbsp;only a slight boost, at best.</p>\n<p>Now, let’s look at a potential catalyst that may be more of a needle-mover: the company’s Apple Car project. If its development and launch are successful, it’s not far-fetched to believe this fully autonomous electric vehicle (EV) could give top early-stage names in this space, like Lucid&nbsp;and Rivian, a run for their money.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ba4c0f33eddb42a2022a11999bb87bf2\" tg-width=\"1240\" tg-height=\"698\" width=\"100%\" height=\"auto\"><span>Figure 1: Apple Car prototype.</span></p>\n<p>Not only that, but the Apple Car may also have a shot of grabbing substantial market share from current leader Tesla. However, before putting in a buy order, let’s take a closer look at this catalyst, and its potential near and long-term impact on Apple shares.</p>\n<p><b>AAPL Stock and its Apple Car Catalyst</b></p>\n<p>Before diving in, here’s a brief overview of Apple and its EV project. For years, the company has been at work developing an electric vehicle.</p>\n<p>Before, it was designing both a limited self-driving vehicle, as well as a fully self-driving vehicle. Working on both projects at the same time made sense. It would enable it to launch an EV before fully autonomous capabilities became available.</p>\n<p>But now, with a new leader in charge of the project (Kevin Lynch),Apple is putting all its eggs in the fully autonomous basket. Speeding up its timeline, the company is targeting a 2025 release date for its fully autonomous EV.</p>\n<p>Given its track record, there are high expectations that Apple will meet this deadline and bring out a possible “Tesla killer” in less than four years. However, that’s not to say it’s a foregone conclusion.</p>\n<p><b>The Apple Maven’s Take</b></p>\n<p>Unlike its metaverse catalyst, the Apple Car may offer a lot more upside potential. As Morgan Stanley’s Katy Huberty argued back in November, its launch of a fully self-driving EV could ultimately&nbsp;double both its revenue and market cap.</p>\n<p>The sell-side analyst pointed to many factors to support her case — the company’s large customer base, for one. Also, there is Apple’s past success diving into uncharted territory. For example, the company was a latecomer to mobile communication devices when it launched the iPhone, but it currently holds&nbsp;23%&nbsp;of the market and growing.</p>\n<p>That said, while it has a strong chance of finding success, the Apple Car could still hiccup moving to the delivery stage. In fact, it’s already dealing with some hurdles right now, as seen from recent news of the project&nbsp;losing key engineers to rivals.</p>\n<p>On top of this, with AAPL stock&nbsp;already trading at a stretched forward earnings multiple, this catalyst may already be factored into its valuation. Ms. Huberty sees EV as something that could one day double the share price. Still, her current price target of $200 per share is less than 20% above the $170 per share that AAPL trades for today — suggesting that much of the Apple Car upside to the stock may not come until beyond 2022.</p>\n<p>Bottom line: the Apple Car may be something that helps the company and stock deliver solid long-term financial results and market gains, respectively. At the same time, it may fail to give shares a big jolt in the coming months.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple Stock: Will The Apple Car Be The Ultimate ‘Tesla Killer?’</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple Stock: Will The Apple Car Be The Ultimate ‘Tesla Killer?’\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-23 10:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/apple/other-products/apple-stock-will-the-apple-car-be-the-ultimate-tesla-killer><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Apple’s EV catalyst may help to boost returns in the long run. But in the near-term, it’s likely already priced into AAPL stock.\nLast week, we broke down Apple stock and its metaverse catalyst. ...</p>\n\n<a href=\"https://www.thestreet.com/apple/other-products/apple-stock-will-the-apple-car-be-the-ultimate-tesla-killer\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果","TSLA":"特斯拉"},"source_url":"https://www.thestreet.com/apple/other-products/apple-stock-will-the-apple-car-be-the-ultimate-tesla-killer","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1141555850","content_text":"Apple’s EV catalyst may help to boost returns in the long run. But in the near-term, it’s likely already priced into AAPL stock.\nLast week, we broke down Apple stock and its metaverse catalyst. Specifically, why the tech giant’s move into AR (augmented reality) and VR (virtual reality) hardware may give shares only a slight boost, at best.\nNow, let’s look at a potential catalyst that may be more of a needle-mover: the company’s Apple Car project. If its development and launch are successful, it’s not far-fetched to believe this fully autonomous electric vehicle (EV) could give top early-stage names in this space, like Lucid and Rivian, a run for their money.\nFigure 1: Apple Car prototype.\nNot only that, but the Apple Car may also have a shot of grabbing substantial market share from current leader Tesla. However, before putting in a buy order, let’s take a closer look at this catalyst, and its potential near and long-term impact on Apple shares.\nAAPL Stock and its Apple Car Catalyst\nBefore diving in, here’s a brief overview of Apple and its EV project. For years, the company has been at work developing an electric vehicle.\nBefore, it was designing both a limited self-driving vehicle, as well as a fully self-driving vehicle. Working on both projects at the same time made sense. It would enable it to launch an EV before fully autonomous capabilities became available.\nBut now, with a new leader in charge of the project (Kevin Lynch),Apple is putting all its eggs in the fully autonomous basket. Speeding up its timeline, the company is targeting a 2025 release date for its fully autonomous EV.\nGiven its track record, there are high expectations that Apple will meet this deadline and bring out a possible “Tesla killer” in less than four years. However, that’s not to say it’s a foregone conclusion.\nThe Apple Maven’s Take\nUnlike its metaverse catalyst, the Apple Car may offer a lot more upside potential. As Morgan Stanley’s Katy Huberty argued back in November, its launch of a fully self-driving EV could ultimately double both its revenue and market cap.\nThe sell-side analyst pointed to many factors to support her case — the company’s large customer base, for one. Also, there is Apple’s past success diving into uncharted territory. For example, the company was a latecomer to mobile communication devices when it launched the iPhone, but it currently holds 23% of the market and growing.\nThat said, while it has a strong chance of finding success, the Apple Car could still hiccup moving to the delivery stage. In fact, it’s already dealing with some hurdles right now, as seen from recent news of the project losing key engineers to rivals.\nOn top of this, with AAPL stock already trading at a stretched forward earnings multiple, this catalyst may already be factored into its valuation. Ms. Huberty sees EV as something that could one day double the share price. Still, her current price target of $200 per share is less than 20% above the $170 per share that AAPL trades for today — suggesting that much of the Apple Car upside to the stock may not come until beyond 2022.\nBottom line: the Apple Car may be something that helps the company and stock deliver solid long-term financial results and market gains, respectively. At the same time, it may fail to give shares a big jolt in the coming months.","news_type":1,"symbols_score_info":{"AAPL":0.9,"TSLA":0.9}},"isVote":1,"tweetType":1,"viewCount":1801,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691410388,"gmtCreate":1640226641093,"gmtModify":1640226641093,"author":{"id":"4087961992375920","authorId":"4087961992375920","name":"larrylim11","avatar":"https://static.tigerbbs.com/b349c02fde492311c83f02b5acc9f8dd","crmLevel":13,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087961992375920","authorIdStr":"4087961992375920"},"themes":[],"htmlText":"Keep going!","listText":"Keep going!","text":"Keep going!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/691410388","repostId":"2193113147","repostType":4,"isVote":1,"tweetType":1,"viewCount":1710,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691292885,"gmtCreate":1640191003765,"gmtModify":1640191003765,"author":{"id":"4087961992375920","authorId":"4087961992375920","name":"larrylim11","avatar":"https://static.tigerbbs.com/b349c02fde492311c83f02b5acc9f8dd","crmLevel":13,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087961992375920","authorIdStr":"4087961992375920"},"themes":[],"htmlText":"Market will go back up!","listText":"Market will go back up!","text":"Market will go back up!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691292885","isVote":1,"tweetType":1,"viewCount":1407,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691293403,"gmtCreate":1640190705944,"gmtModify":1640190719185,"author":{"id":"4087961992375920","authorId":"4087961992375920","name":"larrylim11","avatar":"https://static.tigerbbs.com/b349c02fde492311c83f02b5acc9f8dd","crmLevel":13,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087961992375920","authorIdStr":"4087961992375920"},"themes":[],"htmlText":"Good stuff","listText":"Good stuff","text":"Good stuff","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691293403","repostId":"1169752126","repostType":4,"repost":{"id":"1169752126","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640186708,"share":"https://www.laohu8.com/m/news/1169752126?lang=&edition=full","pubTime":"2021-12-22 23:25","market":"us","language":"en","title":"Why Paychex Shares Are Making New All-Time Highs Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1169752126","media":"Benzinga","summary":"Paychex Inc is trading higher Wednesday after the company announced better-than-expected fiscal seco","content":"<p><b>Paychex Inc</b>&nbsp;is trading higher Wednesday after the company announced better-than-expected fiscal second-quarter 2022 financial results.</p>\n<p>Paychex reported quarterly adjusted&nbsp;earnings of 91 cents per share, which beat the estimate of 80 cents per share. The company reported quarterly revenue of $1.11 billion, which beat the estimate of $1.06 billion.</p>\n<p>Paychex said it expects fiscal-year 2022 revenue growth of 10% to 11%.</p>\n<p>\"We posted strong financial results for the second quarter of fiscal 2022, with growth of 13% in total revenue and 21% in diluted earnings per share. Results were driven by growth in employees within our client base and continued strong sales growth and client retention,\" said&nbsp;<b>Martin Mucci</b>, chairman and CEO of Paychex.</p>\n<p>Paychex is a leading provider of payroll, human capital management&nbsp;and insurance solutions servicing small and midsize clients primarily in the United States.</p>\n<p><b>PAYX Price Action:</b>Paychex has traded as low as $85.30 over a 52-week period. It's making new 52-week highs during Wednesday's trading session.</p>\n<p>The stock was up 5.54% at $133.44.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Paychex Shares Are Making New All-Time Highs Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Paychex Shares Are Making New All-Time Highs Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-12-22 23:25</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Paychex Inc</b>&nbsp;is trading higher Wednesday after the company announced better-than-expected fiscal second-quarter 2022 financial results.</p>\n<p>Paychex reported quarterly adjusted&nbsp;earnings of 91 cents per share, which beat the estimate of 80 cents per share. The company reported quarterly revenue of $1.11 billion, which beat the estimate of $1.06 billion.</p>\n<p>Paychex said it expects fiscal-year 2022 revenue growth of 10% to 11%.</p>\n<p>\"We posted strong financial results for the second quarter of fiscal 2022, with growth of 13% in total revenue and 21% in diluted earnings per share. Results were driven by growth in employees within our client base and continued strong sales growth and client retention,\" said&nbsp;<b>Martin Mucci</b>, chairman and CEO of Paychex.</p>\n<p>Paychex is a leading provider of payroll, human capital management&nbsp;and insurance solutions servicing small and midsize clients primarily in the United States.</p>\n<p><b>PAYX Price Action:</b>Paychex has traded as low as $85.30 over a 52-week period. It's making new 52-week highs during Wednesday's trading session.</p>\n<p>The stock was up 5.54% at $133.44.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PAYX":"沛齐"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1169752126","content_text":"Paychex Inc is trading higher Wednesday after the company announced better-than-expected fiscal second-quarter 2022 financial results.\nPaychex reported quarterly adjusted earnings of 91 cents per share, which beat the estimate of 80 cents per share. The company reported quarterly revenue of $1.11 billion, which beat the estimate of $1.06 billion.\nPaychex said it expects fiscal-year 2022 revenue growth of 10% to 11%.\n\"We posted strong financial results for the second quarter of fiscal 2022, with growth of 13% in total revenue and 21% in diluted earnings per share. Results were driven by growth in employees within our client base and continued strong sales growth and client retention,\" said Martin Mucci, chairman and CEO of Paychex.\nPaychex is a leading provider of payroll, human capital management and insurance solutions servicing small and midsize clients primarily in the United States.\nPAYX Price Action:Paychex has traded as low as $85.30 over a 52-week period. It's making new 52-week highs during Wednesday's trading session.\nThe stock was up 5.54% at $133.44.","news_type":1,"symbols_score_info":{"PAYX":0.9}},"isVote":1,"tweetType":1,"viewCount":2224,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699862235,"gmtCreate":1639782488972,"gmtModify":1639782488972,"author":{"id":"4087961992375920","authorId":"4087961992375920","name":"larrylim11","avatar":"https://static.tigerbbs.com/b349c02fde492311c83f02b5acc9f8dd","crmLevel":13,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087961992375920","authorIdStr":"4087961992375920"},"themes":[],"htmlText":"Good stuff","listText":"Good stuff","text":"Good stuff","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/699862235","isVote":1,"tweetType":1,"viewCount":1350,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690559633,"gmtCreate":1639696351853,"gmtModify":1639696351937,"author":{"id":"4087961992375920","authorId":"4087961992375920","name":"larrylim11","avatar":"https://static.tigerbbs.com/b349c02fde492311c83f02b5acc9f8dd","crmLevel":13,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087961992375920","authorIdStr":"4087961992375920"},"themes":[],"htmlText":"Good stuff&nbsp;","listText":"Good stuff&nbsp;","text":"Good stuff","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/690559633","repostId":"1154960652","repostType":4,"repost":{"id":"1154960652","kind":"news","pubTimestamp":1639695603,"share":"https://www.laohu8.com/m/news/1154960652?lang=&edition=full","pubTime":"2021-12-17 07:00","market":"us","language":"en","title":"CDC Advisers Recommend Pfizer, Moderna Covid-19 Vaccines Over J&J’s","url":"https://stock-news.laohu8.com/highlight/detail?id=1154960652","media":"The Wall Street Journal","summary":"U.S. vaccine advisers recommended adults take a Covid-19 vaccine from Pfizer Inc. PFE 4.17% or Moder","content":"<p>U.S. vaccine advisers recommended adults take a Covid-19 vaccine from Pfizer Inc. PFE 4.17% or Moderna Inc. MRNA -0.44% over Johnson &amp; Johnson’s JNJ 1.09% after health authorities said the rate of a rare but serious blood-clotting condition was higher than previously detected.</p>\n<p></p>\n<p>The Advisory Committee on Immunization Practices voted 15 to 0 to make the recommendation Thursday after hearing updates from Centers for Disease Control and Prevention officials on reports of J&amp;J vaccine recipients experiencing blood clots combined with low blood-platelet levels.</p>\n<p></p>\n<p>The updated position is likely to deal another blow to the use of the J&amp;J shot, whose uptake had been hurt by manufacturing issues and earlier reports of the blood-clotting condition.</p>\n<p></p>\n<p>There have been at least 54 cases of the condition, thrombosis with thrombocytopenia syndrome, or TTS, among J&amp;J vaccine recipients in the U.S., including nine resulting in deaths, CDC officials said Thursday.</p>\n<p></p>\n<p>The rate of cases is higher than previously estimated in both men and women, and in a wider age range, the officials said.</p>\n<p></p>\n<p>“I just cannot recommend vaccines associated with a condition that may lead to death,” said committee member Pablo Sanchez, a pediatric infectious-disease specialist at the Ohio State University-Nationwide Children’s Hospital in Columbus, Ohio.</p>\n<p></p>\n<p>J&amp;J said it remained confident in the overall positive benefit-risk profile of its vaccine. “The safety and well-being of those who use the Johnson &amp; Johnson vaccine continues to be our number one priority,” said Mathai Mammen, global head of J&amp;J’s pharmaceutical research and development.</p>\n<p></p>\n<p>He said the company will work with the CDC on next steps, and strongly supports education about rare events such as TTS, and how to manage it.</p>\n<p></p>\n<p>J&amp;J’s Covid-19 vaccine is based on a different technology than the messenger RNA used in the Pfizer and Moderna shots.</p>\n<p></p>\n<p>J&amp;J’s vaccine includes a harmless version of a virus that can cause the common cold, which is engineered to contain genetic instructions that set off an immune response against the coronavirus. The mRNA vaccines don’t contain any viral material, and use a different way of delivering a genetic code that sets off an immune response against the coronavirus.</p>\n<p></p>\n<p>Earlier this year, federal health authorities paused the use of J&amp;J’s vaccine while they investigated the condition TTS. Use of the vaccine resumed in April after health authorities concluded its benefits still outweighed the risks.</p>\n<p></p>\n<p>The ACIP, which advises the CDC on vaccine policy, voted in April to resume use of J&amp;J’s vaccine, after meeting twice to discuss the issue. Warnings about the risk were added to fact sheets given to vaccine providers and recipients, including that the risk appeared highest among women ages 30 to 49.</p>\n<p>At that time, a total of 15 cases of TTS had been reported among nearly 7 million vaccine doses administered. All of the cases occurred in women between the ages of 18 and 59, with a median age of 37 years. Symptoms developed between six and 15 days after vaccination.</p>\n<p></p>\n<p>As of Aug. 31, CDC officials said at the advisers’ meeting, about 3.8 cases of TTS were reported for every million doses of J&amp;J vaccine administered, across all recipients. The rate was highest among women ages 30 to 39, at 10.6 per million doses.</p>\n<p></p>\n<p>CDC officials also said that among those who develop TTS, the fatality rate was about 15%. The people who died deteriorated quickly after being admitted to the hospital, officials said.</p>\n<p></p>\n<p>CDC officials said getting J&amp;J’s vaccine was still superior to not getting vaccinated, but the balance between the benefits and risks for the messenger RNA vaccines from Pfizer-BioNTech and Moderna was superior to J&amp;J’s. And the current supply of mRNA vaccines in the U.S. is adequate, unlike earlier in the year.</p>\n<p></p>\n<p>A recommendation by the ACIP isn’t binding on vaccine providers or recipients, but it will carry significant weight because it has been rare for the committee to express a preference for one vaccine over another.</p>\n<p></p>\n<p></p>\n<p>Some committee members said that the J&amp;J vaccine should remain available for people who aren’t able to take the mRNA vaccines.</p>\n<p></p>\n<p>Health officials say people with an allergy to ingredients in the mRNA vaccines, or who have had a severe allergic reaction to a dose of those vaccines, should not receive them.</p>\n<p></p>\n<p>The mRNA vaccines also carry a risk of causing heart-inflammation conditions including myocarditis, particularly among males under the age of 30. Yet health officials have said the benefits of preventing Covid-19 hospitalizations and deaths outweigh the myocarditis risk.</p>\n<p></p>\n<p>Penny Heaton, global therapeutic area head of vaccines at J&amp;J, told committee members that the company has been monitoring the safety of the vaccine, including the TTS risk. The vaccine is a life-saving tool, she said, and the company is supplying hundreds of millions of doses around the world.</p>\n<p></p>\n<p>Partly because of the safety concerns, J&amp;J’s single-dose vaccine has been used much less than the two-dose vaccines from Moderna and Pfizer with its partner BioNTech SE.</p>\n<p></p>\n<p>About 16.1 million people in the U.S. have received J&amp;J’s vaccine, according to the CDC. About 870,000 booster doses of J&amp;J’s vaccine have been administered.</p>\n<p></p>\n<p>More than 113 million people have received two doses of the Pfizer-BioNTech vaccine and more than 72 million have received the two-dose Moderna vaccine in the U.S. More than 30 million booster doses of the Pfizer vaccine and 24 million Moderna booster doses have been administered in the U.S., according to the CDC.</p>\n<p></p>\n<p>J&amp;J said Thursday it recently updated the fact sheet for its vaccine to say that it shouldn’t be administered to people who previously experienced TTS after receiving a prior dose of either the J&amp;J vaccine or other vaccines with a similar adenovirus-based design.</p>\n<p></p>\n<p>Other shots with a similar design include AstraZeneca PLC’s Covid-19 vaccine, which is available outside the U.S. but not in the U.S.</p>\n<p></p>\n<p>The recommendation threatens to affect support for J&amp;J’s vaccine outside the U.S., including in countries struggling to increase their supplies of doses, just as J&amp;J has begun shipping shots that Merck &amp; Co. helped produce.</p>\n<p></p>\n<p>The CDC advisory committee members didn’t consider a recommendation against the use of J&amp;J’s vaccine partly because such a move could undermine confidence in the vaccine in countries where people have better access to J&amp;J’s vaccine over the mRNA vaccines.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CDC Advisers Recommend Pfizer, Moderna Covid-19 Vaccines Over J&J’s</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCDC Advisers Recommend Pfizer, Moderna Covid-19 Vaccines Over J&J’s\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-17 07:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.wsj.com/articles/cdc-advisers-review-blood-clotting-risk-associated-with-j-js-covid-19-vaccine-11639662363?mod=hp_lead_pos1><strong>The Wall Street Journal</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>U.S. vaccine advisers recommended adults take a Covid-19 vaccine from Pfizer Inc. PFE 4.17% or Moderna Inc. MRNA -0.44% over Johnson & Johnson’s JNJ 1.09% after health authorities said the rate of a ...</p>\n\n<a href=\"https://www.wsj.com/articles/cdc-advisers-review-blood-clotting-risk-associated-with-j-js-covid-19-vaccine-11639662363?mod=hp_lead_pos1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","MRNA":"Moderna, Inc."},"source_url":"https://www.wsj.com/articles/cdc-advisers-review-blood-clotting-risk-associated-with-j-js-covid-19-vaccine-11639662363?mod=hp_lead_pos1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1154960652","content_text":"U.S. vaccine advisers recommended adults take a Covid-19 vaccine from Pfizer Inc. PFE 4.17% or Moderna Inc. MRNA -0.44% over Johnson & Johnson’s JNJ 1.09% after health authorities said the rate of a rare but serious blood-clotting condition was higher than previously detected.\n\nThe Advisory Committee on Immunization Practices voted 15 to 0 to make the recommendation Thursday after hearing updates from Centers for Disease Control and Prevention officials on reports of J&J vaccine recipients experiencing blood clots combined with low blood-platelet levels.\n\nThe updated position is likely to deal another blow to the use of the J&J shot, whose uptake had been hurt by manufacturing issues and earlier reports of the blood-clotting condition.\n\nThere have been at least 54 cases of the condition, thrombosis with thrombocytopenia syndrome, or TTS, among J&J vaccine recipients in the U.S., including nine resulting in deaths, CDC officials said Thursday.\n\nThe rate of cases is higher than previously estimated in both men and women, and in a wider age range, the officials said.\n\n“I just cannot recommend vaccines associated with a condition that may lead to death,” said committee member Pablo Sanchez, a pediatric infectious-disease specialist at the Ohio State University-Nationwide Children’s Hospital in Columbus, Ohio.\n\nJ&J said it remained confident in the overall positive benefit-risk profile of its vaccine. “The safety and well-being of those who use the Johnson & Johnson vaccine continues to be our number one priority,” said Mathai Mammen, global head of J&J’s pharmaceutical research and development.\n\nHe said the company will work with the CDC on next steps, and strongly supports education about rare events such as TTS, and how to manage it.\n\nJ&J’s Covid-19 vaccine is based on a different technology than the messenger RNA used in the Pfizer and Moderna shots.\n\nJ&J’s vaccine includes a harmless version of a virus that can cause the common cold, which is engineered to contain genetic instructions that set off an immune response against the coronavirus. The mRNA vaccines don’t contain any viral material, and use a different way of delivering a genetic code that sets off an immune response against the coronavirus.\n\nEarlier this year, federal health authorities paused the use of J&J’s vaccine while they investigated the condition TTS. Use of the vaccine resumed in April after health authorities concluded its benefits still outweighed the risks.\n\nThe ACIP, which advises the CDC on vaccine policy, voted in April to resume use of J&J’s vaccine, after meeting twice to discuss the issue. Warnings about the risk were added to fact sheets given to vaccine providers and recipients, including that the risk appeared highest among women ages 30 to 49.\nAt that time, a total of 15 cases of TTS had been reported among nearly 7 million vaccine doses administered. All of the cases occurred in women between the ages of 18 and 59, with a median age of 37 years. Symptoms developed between six and 15 days after vaccination.\n\nAs of Aug. 31, CDC officials said at the advisers’ meeting, about 3.8 cases of TTS were reported for every million doses of J&J vaccine administered, across all recipients. The rate was highest among women ages 30 to 39, at 10.6 per million doses.\n\nCDC officials also said that among those who develop TTS, the fatality rate was about 15%. The people who died deteriorated quickly after being admitted to the hospital, officials said.\n\nCDC officials said getting J&J’s vaccine was still superior to not getting vaccinated, but the balance between the benefits and risks for the messenger RNA vaccines from Pfizer-BioNTech and Moderna was superior to J&J’s. And the current supply of mRNA vaccines in the U.S. is adequate, unlike earlier in the year.\n\nA recommendation by the ACIP isn’t binding on vaccine providers or recipients, but it will carry significant weight because it has been rare for the committee to express a preference for one vaccine over another.\n\n\nSome committee members said that the J&J vaccine should remain available for people who aren’t able to take the mRNA vaccines.\n\nHealth officials say people with an allergy to ingredients in the mRNA vaccines, or who have had a severe allergic reaction to a dose of those vaccines, should not receive them.\n\nThe mRNA vaccines also carry a risk of causing heart-inflammation conditions including myocarditis, particularly among males under the age of 30. Yet health officials have said the benefits of preventing Covid-19 hospitalizations and deaths outweigh the myocarditis risk.\n\nPenny Heaton, global therapeutic area head of vaccines at J&J, told committee members that the company has been monitoring the safety of the vaccine, including the TTS risk. The vaccine is a life-saving tool, she said, and the company is supplying hundreds of millions of doses around the world.\n\nPartly because of the safety concerns, J&J’s single-dose vaccine has been used much less than the two-dose vaccines from Moderna and Pfizer with its partner BioNTech SE.\n\nAbout 16.1 million people in the U.S. have received J&J’s vaccine, according to the CDC. About 870,000 booster doses of J&J’s vaccine have been administered.\n\nMore than 113 million people have received two doses of the Pfizer-BioNTech vaccine and more than 72 million have received the two-dose Moderna vaccine in the U.S. More than 30 million booster doses of the Pfizer vaccine and 24 million Moderna booster doses have been administered in the U.S., according to the CDC.\n\nJ&J said Thursday it recently updated the fact sheet for its vaccine to say that it shouldn’t be administered to people who previously experienced TTS after receiving a prior dose of either the J&J vaccine or other vaccines with a similar adenovirus-based design.\n\nOther shots with a similar design include AstraZeneca PLC’s Covid-19 vaccine, which is available outside the U.S. but not in the U.S.\n\nThe recommendation threatens to affect support for J&J’s vaccine outside the U.S., including in countries struggling to increase their supplies of doses, just as J&J has begun shipping shots that Merck & Co. helped produce.\n\nThe CDC advisory committee members didn’t consider a recommendation against the use of J&J’s vaccine partly because such a move could undermine confidence in the vaccine in countries where people have better access to J&J’s vaccine over the mRNA vaccines.","news_type":1,"symbols_score_info":{"MRNA":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":2645,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690550452,"gmtCreate":1639696288846,"gmtModify":1639696289837,"author":{"id":"4087961992375920","authorId":"4087961992375920","name":"larrylim11","avatar":"https://static.tigerbbs.com/b349c02fde492311c83f02b5acc9f8dd","crmLevel":13,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087961992375920","authorIdStr":"4087961992375920"},"themes":[],"htmlText":"Good stuff!","listText":"Good stuff!","text":"Good stuff!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690550452","repostId":"2192920942","repostType":4,"isVote":1,"tweetType":1,"viewCount":1407,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":842621749,"gmtCreate":1636171939170,"gmtModify":1636171939265,"author":{"id":"4087961992375920","authorId":"4087961992375920","name":"larrylim11","avatar":"https://static.tigerbbs.com/b349c02fde492311c83f02b5acc9f8dd","crmLevel":13,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087961992375920","authorIdStr":"4087961992375920"},"themes":[],"htmlText":"Whee!","listText":"Whee!","text":"Whee!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/842621749","repostId":"850756569","repostType":1,"repost":{"id":850756569,"gmtCreate":1634631211448,"gmtModify":1635853120757,"author":{"id":"36984908995200","authorId":"36984908995200","name":"小虎活动","avatar":"https://static.tigerbbs.com/9e396d03155923b283948d2dec9191f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"36984908995200","authorIdStr":"36984908995200"},"themes":[],"title":"[Halloween Game] Trade or Treat!","htmlText":"Hello, dear Tigers!&nbsp; Happy&nbsp;Halloween!&nbsp;🎃🎃🎃&nbsp;&nbsp; <a href=\"https://www.tigerbrokers.com.sg/activity/market/2021/halloween/?lang=en_US#/\" target=\"_blank\">Tap&nbsp;here&nbsp;to&nbsp;play the Halloween game,&nbsp;and&nbsp;you&nbsp;stand&nbsp;a&nbsp;chance&nbsp;to win various rewards!&nbsp;</a> Promotion Period: October 27, 2021 18:00 - November 9, 2021 18:00 (SGT) 1.&nbsp;How to Participate? All Tiger clients may collect points which can be used to redeem rewards by taking part in the Trade or Treating Game. All existing Tiger clients will have 2 game attempts. Clients can get more game attempts by completing different tasks, such as 'Invite a friend' or 'Share Halloween Game'.&nbsp; 2.&nbsp;How to collect points? Each player has 30 seconds to catch falling candies while av","listText":"Hello, dear Tigers!&nbsp; Happy&nbsp;Halloween!&nbsp;🎃🎃🎃&nbsp;&nbsp; <a href=\"https://www.tigerbrokers.com.sg/activity/market/2021/halloween/?lang=en_US#/\" target=\"_blank\">Tap&nbsp;here&nbsp;to&nbsp;play the Halloween game,&nbsp;and&nbsp;you&nbsp;stand&nbsp;a&nbsp;chance&nbsp;to win various rewards!&nbsp;</a> Promotion Period: October 27, 2021 18:00 - November 9, 2021 18:00 (SGT) 1.&nbsp;How to Participate? All Tiger clients may collect points which can be used to redeem rewards by taking part in the Trade or Treating Game. All existing Tiger clients will have 2 game attempts. Clients can get more game attempts by completing different tasks, such as 'Invite a friend' or 'Share Halloween Game'.&nbsp; 2.&nbsp;How to collect points? Each player has 30 seconds to catch falling candies while av","text":"Hello, dear Tigers! Happy Halloween! 🎃🎃🎃 Tap here to play the Halloween game, and you stand a chance to win various rewards! Promotion Period: October 27, 2021 18:00 - November 9, 2021 18:00 (SGT) 1. How to Participate? All Tiger clients may collect points which can be used to redeem rewards by taking part in the Trade or Treating Game. All existing Tiger clients will have 2 game attempts. Clients can get more game attempts by completing different tasks, such as 'Invite a friend' or 'Share Halloween Game'. 2. How to collect points? Each player has 30 seconds to catch falling candies while av","images":[],"top":1,"highlighted":2,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/850756569","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":1411,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":848103890,"gmtCreate":1635980926483,"gmtModify":1635980926610,"author":{"id":"4087961992375920","authorId":"4087961992375920","name":"larrylim11","avatar":"https://static.tigerbbs.com/b349c02fde492311c83f02b5acc9f8dd","crmLevel":13,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087961992375920","authorIdStr":"4087961992375920"},"themes":[],"htmlText":"Yes!","listText":"Yes!","text":"Yes!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/848103890","repostId":"850756569","repostType":1,"repost":{"id":850756569,"gmtCreate":1634631211448,"gmtModify":1635853120757,"author":{"id":"36984908995200","authorId":"36984908995200","name":"小虎活动","avatar":"https://static.tigerbbs.com/9e396d03155923b283948d2dec9191f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"36984908995200","authorIdStr":"36984908995200"},"themes":[],"title":"[Halloween Game] Trade or Treat!","htmlText":"Hello, dear Tigers!&nbsp; Happy&nbsp;Halloween!&nbsp;🎃🎃🎃&nbsp;&nbsp; <a href=\"https://www.tigerbrokers.com.sg/activity/market/2021/halloween/?lang=en_US#/\" target=\"_blank\">Tap&nbsp;here&nbsp;to&nbsp;play the Halloween game,&nbsp;and&nbsp;you&nbsp;stand&nbsp;a&nbsp;chance&nbsp;to win various rewards!&nbsp;</a> Promotion Period: October 27, 2021 18:00 - November 9, 2021 18:00 (SGT) 1.&nbsp;How to Participate? All Tiger clients may collect points which can be used to redeem rewards by taking part in the Trade or Treating Game. All existing Tiger clients will have 2 game attempts. Clients can get more game attempts by completing different tasks, such as 'Invite a friend' or 'Share Halloween Game'.&nbsp; 2.&nbsp;How to collect points? Each player has 30 seconds to catch falling candies while av","listText":"Hello, dear Tigers!&nbsp; Happy&nbsp;Halloween!&nbsp;🎃🎃🎃&nbsp;&nbsp; <a href=\"https://www.tigerbrokers.com.sg/activity/market/2021/halloween/?lang=en_US#/\" target=\"_blank\">Tap&nbsp;here&nbsp;to&nbsp;play the Halloween game,&nbsp;and&nbsp;you&nbsp;stand&nbsp;a&nbsp;chance&nbsp;to win various rewards!&nbsp;</a> Promotion Period: October 27, 2021 18:00 - November 9, 2021 18:00 (SGT) 1.&nbsp;How to Participate? All Tiger clients may collect points which can be used to redeem rewards by taking part in the Trade or Treating Game. All existing Tiger clients will have 2 game attempts. Clients can get more game attempts by completing different tasks, such as 'Invite a friend' or 'Share Halloween Game'.&nbsp; 2.&nbsp;How to collect points? Each player has 30 seconds to catch falling candies while av","text":"Hello, dear Tigers! Happy Halloween! 🎃🎃🎃 Tap here to play the Halloween game, and you stand a chance to win various rewards! Promotion Period: October 27, 2021 18:00 - November 9, 2021 18:00 (SGT) 1. How to Participate? All Tiger clients may collect points which can be used to redeem rewards by taking part in the Trade or Treating Game. All existing Tiger clients will have 2 game attempts. Clients can get more game attempts by completing different tasks, such as 'Invite a friend' or 'Share Halloween Game'. 2. How to collect points? Each player has 30 seconds to catch falling candies while av","images":[],"top":1,"highlighted":2,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/850756569","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":452,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":841123231,"gmtCreate":1635897114472,"gmtModify":1635897114472,"author":{"id":"4087961992375920","authorId":"4087961992375920","name":"larrylim11","avatar":"https://static.tigerbbs.com/b349c02fde492311c83f02b5acc9f8dd","crmLevel":13,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087961992375920","authorIdStr":"4087961992375920"},"themes":[],"htmlText":"Woo hoo!","listText":"Woo hoo!","text":"Woo hoo!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/841123231","repostId":"850756569","repostType":1,"repost":{"id":850756569,"gmtCreate":1634631211448,"gmtModify":1635853120757,"author":{"id":"36984908995200","authorId":"36984908995200","name":"小虎活动","avatar":"https://static.tigerbbs.com/9e396d03155923b283948d2dec9191f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"36984908995200","authorIdStr":"36984908995200"},"themes":[],"title":"[Halloween Game] Trade or Treat!","htmlText":"Hello, dear Tigers!&nbsp; Happy&nbsp;Halloween!&nbsp;🎃🎃🎃&nbsp;&nbsp; <a href=\"https://www.tigerbrokers.com.sg/activity/market/2021/halloween/?lang=en_US#/\" target=\"_blank\">Tap&nbsp;here&nbsp;to&nbsp;play the Halloween game,&nbsp;and&nbsp;you&nbsp;stand&nbsp;a&nbsp;chance&nbsp;to win various rewards!&nbsp;</a> Promotion Period: October 27, 2021 18:00 - November 9, 2021 18:00 (SGT) 1.&nbsp;How to Participate? All Tiger clients may collect points which can be used to redeem rewards by taking part in the Trade or Treating Game. All existing Tiger clients will have 2 game attempts. Clients can get more game attempts by completing different tasks, such as 'Invite a friend' or 'Share Halloween Game'.&nbsp; 2.&nbsp;How to collect points? Each player has 30 seconds to catch falling candies while av","listText":"Hello, dear Tigers!&nbsp; Happy&nbsp;Halloween!&nbsp;🎃🎃🎃&nbsp;&nbsp; <a href=\"https://www.tigerbrokers.com.sg/activity/market/2021/halloween/?lang=en_US#/\" target=\"_blank\">Tap&nbsp;here&nbsp;to&nbsp;play the Halloween game,&nbsp;and&nbsp;you&nbsp;stand&nbsp;a&nbsp;chance&nbsp;to win various rewards!&nbsp;</a> Promotion Period: October 27, 2021 18:00 - November 9, 2021 18:00 (SGT) 1.&nbsp;How to Participate? All Tiger clients may collect points which can be used to redeem rewards by taking part in the Trade or Treating Game. All existing Tiger clients will have 2 game attempts. Clients can get more game attempts by completing different tasks, such as 'Invite a friend' or 'Share Halloween Game'.&nbsp; 2.&nbsp;How to collect points? Each player has 30 seconds to catch falling candies while av","text":"Hello, dear Tigers! Happy Halloween! 🎃🎃🎃 Tap here to play the Halloween game, and you stand a chance to win various rewards! Promotion Period: October 27, 2021 18:00 - November 9, 2021 18:00 (SGT) 1. How to Participate? All Tiger clients may collect points which can be used to redeem rewards by taking part in the Trade or Treating Game. All existing Tiger clients will have 2 game attempts. Clients can get more game attempts by completing different tasks, such as 'Invite a friend' or 'Share Halloween Game'. 2. How to collect points? Each player has 30 seconds to catch falling candies while av","images":[],"top":1,"highlighted":2,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/850756569","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":518,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":144370844,"gmtCreate":1626270128588,"gmtModify":1633928446212,"author":{"id":"4087961992375920","authorId":"4087961992375920","name":"larrylim11","avatar":"https://static.tigerbbs.com/b349c02fde492311c83f02b5acc9f8dd","crmLevel":13,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087961992375920","authorIdStr":"4087961992375920"},"themes":[],"htmlText":"Good stuff","listText":"Good stuff","text":"Good stuff","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/144370844","repostId":"1158673076","repostType":4,"isVote":1,"tweetType":1,"viewCount":147,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":143020380,"gmtCreate":1625753028240,"gmtModify":1633937686390,"author":{"id":"4087961992375920","authorId":"4087961992375920","name":"larrylim11","avatar":"https://static.tigerbbs.com/b349c02fde492311c83f02b5acc9f8dd","crmLevel":13,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087961992375920","authorIdStr":"4087961992375920"},"themes":[],"htmlText":"Oh no..","listText":"Oh no..","text":"Oh no..","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/143020380","repostId":"1195364777","repostType":4,"isVote":1,"tweetType":1,"viewCount":150,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":159252598,"gmtCreate":1624971958014,"gmtModify":1633946386466,"author":{"id":"4087961992375920","authorId":"4087961992375920","name":"larrylim11","avatar":"https://static.tigerbbs.com/b349c02fde492311c83f02b5acc9f8dd","crmLevel":13,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087961992375920","authorIdStr":"4087961992375920"},"themes":[],"htmlText":"Good stuff!","listText":"Good stuff!","text":"Good stuff!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/159252598","repostId":"1100563900","repostType":2,"isVote":1,"tweetType":1,"viewCount":210,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":691410388,"gmtCreate":1640226641093,"gmtModify":1640226641093,"author":{"id":"4087961992375920","authorId":"4087961992375920","name":"larrylim11","avatar":"https://static.tigerbbs.com/b349c02fde492311c83f02b5acc9f8dd","crmLevel":13,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087961992375920","authorIdStr":"4087961992375920"},"themes":[],"htmlText":"Keep going!","listText":"Keep going!","text":"Keep going!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/691410388","repostId":"2193113147","repostType":4,"isVote":1,"tweetType":1,"viewCount":1710,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691293403,"gmtCreate":1640190705944,"gmtModify":1640190719185,"author":{"id":"4087961992375920","authorId":"4087961992375920","name":"larrylim11","avatar":"https://static.tigerbbs.com/b349c02fde492311c83f02b5acc9f8dd","crmLevel":13,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087961992375920","authorIdStr":"4087961992375920"},"themes":[],"htmlText":"Good stuff","listText":"Good stuff","text":"Good stuff","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691293403","repostId":"1169752126","repostType":4,"repost":{"id":"1169752126","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640186708,"share":"https://www.laohu8.com/m/news/1169752126?lang=&edition=full","pubTime":"2021-12-22 23:25","market":"us","language":"en","title":"Why Paychex Shares Are Making New All-Time Highs Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1169752126","media":"Benzinga","summary":"Paychex Inc is trading higher Wednesday after the company announced better-than-expected fiscal seco","content":"<p><b>Paychex Inc</b>&nbsp;is trading higher Wednesday after the company announced better-than-expected fiscal second-quarter 2022 financial results.</p>\n<p>Paychex reported quarterly adjusted&nbsp;earnings of 91 cents per share, which beat the estimate of 80 cents per share. The company reported quarterly revenue of $1.11 billion, which beat the estimate of $1.06 billion.</p>\n<p>Paychex said it expects fiscal-year 2022 revenue growth of 10% to 11%.</p>\n<p>\"We posted strong financial results for the second quarter of fiscal 2022, with growth of 13% in total revenue and 21% in diluted earnings per share. Results were driven by growth in employees within our client base and continued strong sales growth and client retention,\" said&nbsp;<b>Martin Mucci</b>, chairman and CEO of Paychex.</p>\n<p>Paychex is a leading provider of payroll, human capital management&nbsp;and insurance solutions servicing small and midsize clients primarily in the United States.</p>\n<p><b>PAYX Price Action:</b>Paychex has traded as low as $85.30 over a 52-week period. It's making new 52-week highs during Wednesday's trading session.</p>\n<p>The stock was up 5.54% at $133.44.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Paychex Shares Are Making New All-Time Highs Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Paychex Shares Are Making New All-Time Highs Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-12-22 23:25</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Paychex Inc</b>&nbsp;is trading higher Wednesday after the company announced better-than-expected fiscal second-quarter 2022 financial results.</p>\n<p>Paychex reported quarterly adjusted&nbsp;earnings of 91 cents per share, which beat the estimate of 80 cents per share. The company reported quarterly revenue of $1.11 billion, which beat the estimate of $1.06 billion.</p>\n<p>Paychex said it expects fiscal-year 2022 revenue growth of 10% to 11%.</p>\n<p>\"We posted strong financial results for the second quarter of fiscal 2022, with growth of 13% in total revenue and 21% in diluted earnings per share. Results were driven by growth in employees within our client base and continued strong sales growth and client retention,\" said&nbsp;<b>Martin Mucci</b>, chairman and CEO of Paychex.</p>\n<p>Paychex is a leading provider of payroll, human capital management&nbsp;and insurance solutions servicing small and midsize clients primarily in the United States.</p>\n<p><b>PAYX Price Action:</b>Paychex has traded as low as $85.30 over a 52-week period. It's making new 52-week highs during Wednesday's trading session.</p>\n<p>The stock was up 5.54% at $133.44.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PAYX":"沛齐"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1169752126","content_text":"Paychex Inc is trading higher Wednesday after the company announced better-than-expected fiscal second-quarter 2022 financial results.\nPaychex reported quarterly adjusted earnings of 91 cents per share, which beat the estimate of 80 cents per share. The company reported quarterly revenue of $1.11 billion, which beat the estimate of $1.06 billion.\nPaychex said it expects fiscal-year 2022 revenue growth of 10% to 11%.\n\"We posted strong financial results for the second quarter of fiscal 2022, with growth of 13% in total revenue and 21% in diluted earnings per share. Results were driven by growth in employees within our client base and continued strong sales growth and client retention,\" said Martin Mucci, chairman and CEO of Paychex.\nPaychex is a leading provider of payroll, human capital management and insurance solutions servicing small and midsize clients primarily in the United States.\nPAYX Price Action:Paychex has traded as low as $85.30 over a 52-week period. It's making new 52-week highs during Wednesday's trading session.\nThe stock was up 5.54% at $133.44.","news_type":1,"symbols_score_info":{"PAYX":0.9}},"isVote":1,"tweetType":1,"viewCount":2224,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690559633,"gmtCreate":1639696351853,"gmtModify":1639696351937,"author":{"id":"4087961992375920","authorId":"4087961992375920","name":"larrylim11","avatar":"https://static.tigerbbs.com/b349c02fde492311c83f02b5acc9f8dd","crmLevel":13,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087961992375920","authorIdStr":"4087961992375920"},"themes":[],"htmlText":"Good stuff&nbsp;","listText":"Good stuff&nbsp;","text":"Good stuff","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/690559633","repostId":"1154960652","repostType":4,"repost":{"id":"1154960652","kind":"news","pubTimestamp":1639695603,"share":"https://www.laohu8.com/m/news/1154960652?lang=&edition=full","pubTime":"2021-12-17 07:00","market":"us","language":"en","title":"CDC Advisers Recommend Pfizer, Moderna Covid-19 Vaccines Over J&J’s","url":"https://stock-news.laohu8.com/highlight/detail?id=1154960652","media":"The Wall Street Journal","summary":"U.S. vaccine advisers recommended adults take a Covid-19 vaccine from Pfizer Inc. PFE 4.17% or Moder","content":"<p>U.S. vaccine advisers recommended adults take a Covid-19 vaccine from Pfizer Inc. PFE 4.17% or Moderna Inc. MRNA -0.44% over Johnson &amp; Johnson’s JNJ 1.09% after health authorities said the rate of a rare but serious blood-clotting condition was higher than previously detected.</p>\n<p></p>\n<p>The Advisory Committee on Immunization Practices voted 15 to 0 to make the recommendation Thursday after hearing updates from Centers for Disease Control and Prevention officials on reports of J&amp;J vaccine recipients experiencing blood clots combined with low blood-platelet levels.</p>\n<p></p>\n<p>The updated position is likely to deal another blow to the use of the J&amp;J shot, whose uptake had been hurt by manufacturing issues and earlier reports of the blood-clotting condition.</p>\n<p></p>\n<p>There have been at least 54 cases of the condition, thrombosis with thrombocytopenia syndrome, or TTS, among J&amp;J vaccine recipients in the U.S., including nine resulting in deaths, CDC officials said Thursday.</p>\n<p></p>\n<p>The rate of cases is higher than previously estimated in both men and women, and in a wider age range, the officials said.</p>\n<p></p>\n<p>“I just cannot recommend vaccines associated with a condition that may lead to death,” said committee member Pablo Sanchez, a pediatric infectious-disease specialist at the Ohio State University-Nationwide Children’s Hospital in Columbus, Ohio.</p>\n<p></p>\n<p>J&amp;J said it remained confident in the overall positive benefit-risk profile of its vaccine. “The safety and well-being of those who use the Johnson &amp; Johnson vaccine continues to be our number one priority,” said Mathai Mammen, global head of J&amp;J’s pharmaceutical research and development.</p>\n<p></p>\n<p>He said the company will work with the CDC on next steps, and strongly supports education about rare events such as TTS, and how to manage it.</p>\n<p></p>\n<p>J&amp;J’s Covid-19 vaccine is based on a different technology than the messenger RNA used in the Pfizer and Moderna shots.</p>\n<p></p>\n<p>J&amp;J’s vaccine includes a harmless version of a virus that can cause the common cold, which is engineered to contain genetic instructions that set off an immune response against the coronavirus. The mRNA vaccines don’t contain any viral material, and use a different way of delivering a genetic code that sets off an immune response against the coronavirus.</p>\n<p></p>\n<p>Earlier this year, federal health authorities paused the use of J&amp;J’s vaccine while they investigated the condition TTS. Use of the vaccine resumed in April after health authorities concluded its benefits still outweighed the risks.</p>\n<p></p>\n<p>The ACIP, which advises the CDC on vaccine policy, voted in April to resume use of J&amp;J’s vaccine, after meeting twice to discuss the issue. Warnings about the risk were added to fact sheets given to vaccine providers and recipients, including that the risk appeared highest among women ages 30 to 49.</p>\n<p>At that time, a total of 15 cases of TTS had been reported among nearly 7 million vaccine doses administered. All of the cases occurred in women between the ages of 18 and 59, with a median age of 37 years. Symptoms developed between six and 15 days after vaccination.</p>\n<p></p>\n<p>As of Aug. 31, CDC officials said at the advisers’ meeting, about 3.8 cases of TTS were reported for every million doses of J&amp;J vaccine administered, across all recipients. The rate was highest among women ages 30 to 39, at 10.6 per million doses.</p>\n<p></p>\n<p>CDC officials also said that among those who develop TTS, the fatality rate was about 15%. The people who died deteriorated quickly after being admitted to the hospital, officials said.</p>\n<p></p>\n<p>CDC officials said getting J&amp;J’s vaccine was still superior to not getting vaccinated, but the balance between the benefits and risks for the messenger RNA vaccines from Pfizer-BioNTech and Moderna was superior to J&amp;J’s. And the current supply of mRNA vaccines in the U.S. is adequate, unlike earlier in the year.</p>\n<p></p>\n<p>A recommendation by the ACIP isn’t binding on vaccine providers or recipients, but it will carry significant weight because it has been rare for the committee to express a preference for one vaccine over another.</p>\n<p></p>\n<p></p>\n<p>Some committee members said that the J&amp;J vaccine should remain available for people who aren’t able to take the mRNA vaccines.</p>\n<p></p>\n<p>Health officials say people with an allergy to ingredients in the mRNA vaccines, or who have had a severe allergic reaction to a dose of those vaccines, should not receive them.</p>\n<p></p>\n<p>The mRNA vaccines also carry a risk of causing heart-inflammation conditions including myocarditis, particularly among males under the age of 30. Yet health officials have said the benefits of preventing Covid-19 hospitalizations and deaths outweigh the myocarditis risk.</p>\n<p></p>\n<p>Penny Heaton, global therapeutic area head of vaccines at J&amp;J, told committee members that the company has been monitoring the safety of the vaccine, including the TTS risk. The vaccine is a life-saving tool, she said, and the company is supplying hundreds of millions of doses around the world.</p>\n<p></p>\n<p>Partly because of the safety concerns, J&amp;J’s single-dose vaccine has been used much less than the two-dose vaccines from Moderna and Pfizer with its partner BioNTech SE.</p>\n<p></p>\n<p>About 16.1 million people in the U.S. have received J&amp;J’s vaccine, according to the CDC. About 870,000 booster doses of J&amp;J’s vaccine have been administered.</p>\n<p></p>\n<p>More than 113 million people have received two doses of the Pfizer-BioNTech vaccine and more than 72 million have received the two-dose Moderna vaccine in the U.S. More than 30 million booster doses of the Pfizer vaccine and 24 million Moderna booster doses have been administered in the U.S., according to the CDC.</p>\n<p></p>\n<p>J&amp;J said Thursday it recently updated the fact sheet for its vaccine to say that it shouldn’t be administered to people who previously experienced TTS after receiving a prior dose of either the J&amp;J vaccine or other vaccines with a similar adenovirus-based design.</p>\n<p></p>\n<p>Other shots with a similar design include AstraZeneca PLC’s Covid-19 vaccine, which is available outside the U.S. but not in the U.S.</p>\n<p></p>\n<p>The recommendation threatens to affect support for J&amp;J’s vaccine outside the U.S., including in countries struggling to increase their supplies of doses, just as J&amp;J has begun shipping shots that Merck &amp; Co. helped produce.</p>\n<p></p>\n<p>The CDC advisory committee members didn’t consider a recommendation against the use of J&amp;J’s vaccine partly because such a move could undermine confidence in the vaccine in countries where people have better access to J&amp;J’s vaccine over the mRNA vaccines.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CDC Advisers Recommend Pfizer, Moderna Covid-19 Vaccines Over J&J’s</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCDC Advisers Recommend Pfizer, Moderna Covid-19 Vaccines Over J&J’s\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-17 07:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.wsj.com/articles/cdc-advisers-review-blood-clotting-risk-associated-with-j-js-covid-19-vaccine-11639662363?mod=hp_lead_pos1><strong>The Wall Street Journal</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>U.S. vaccine advisers recommended adults take a Covid-19 vaccine from Pfizer Inc. PFE 4.17% or Moderna Inc. MRNA -0.44% over Johnson & Johnson’s JNJ 1.09% after health authorities said the rate of a ...</p>\n\n<a href=\"https://www.wsj.com/articles/cdc-advisers-review-blood-clotting-risk-associated-with-j-js-covid-19-vaccine-11639662363?mod=hp_lead_pos1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","MRNA":"Moderna, Inc."},"source_url":"https://www.wsj.com/articles/cdc-advisers-review-blood-clotting-risk-associated-with-j-js-covid-19-vaccine-11639662363?mod=hp_lead_pos1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1154960652","content_text":"U.S. vaccine advisers recommended adults take a Covid-19 vaccine from Pfizer Inc. PFE 4.17% or Moderna Inc. MRNA -0.44% over Johnson & Johnson’s JNJ 1.09% after health authorities said the rate of a rare but serious blood-clotting condition was higher than previously detected.\n\nThe Advisory Committee on Immunization Practices voted 15 to 0 to make the recommendation Thursday after hearing updates from Centers for Disease Control and Prevention officials on reports of J&J vaccine recipients experiencing blood clots combined with low blood-platelet levels.\n\nThe updated position is likely to deal another blow to the use of the J&J shot, whose uptake had been hurt by manufacturing issues and earlier reports of the blood-clotting condition.\n\nThere have been at least 54 cases of the condition, thrombosis with thrombocytopenia syndrome, or TTS, among J&J vaccine recipients in the U.S., including nine resulting in deaths, CDC officials said Thursday.\n\nThe rate of cases is higher than previously estimated in both men and women, and in a wider age range, the officials said.\n\n“I just cannot recommend vaccines associated with a condition that may lead to death,” said committee member Pablo Sanchez, a pediatric infectious-disease specialist at the Ohio State University-Nationwide Children’s Hospital in Columbus, Ohio.\n\nJ&J said it remained confident in the overall positive benefit-risk profile of its vaccine. “The safety and well-being of those who use the Johnson & Johnson vaccine continues to be our number one priority,” said Mathai Mammen, global head of J&J’s pharmaceutical research and development.\n\nHe said the company will work with the CDC on next steps, and strongly supports education about rare events such as TTS, and how to manage it.\n\nJ&J’s Covid-19 vaccine is based on a different technology than the messenger RNA used in the Pfizer and Moderna shots.\n\nJ&J’s vaccine includes a harmless version of a virus that can cause the common cold, which is engineered to contain genetic instructions that set off an immune response against the coronavirus. The mRNA vaccines don’t contain any viral material, and use a different way of delivering a genetic code that sets off an immune response against the coronavirus.\n\nEarlier this year, federal health authorities paused the use of J&J’s vaccine while they investigated the condition TTS. Use of the vaccine resumed in April after health authorities concluded its benefits still outweighed the risks.\n\nThe ACIP, which advises the CDC on vaccine policy, voted in April to resume use of J&J’s vaccine, after meeting twice to discuss the issue. Warnings about the risk were added to fact sheets given to vaccine providers and recipients, including that the risk appeared highest among women ages 30 to 49.\nAt that time, a total of 15 cases of TTS had been reported among nearly 7 million vaccine doses administered. All of the cases occurred in women between the ages of 18 and 59, with a median age of 37 years. Symptoms developed between six and 15 days after vaccination.\n\nAs of Aug. 31, CDC officials said at the advisers’ meeting, about 3.8 cases of TTS were reported for every million doses of J&J vaccine administered, across all recipients. The rate was highest among women ages 30 to 39, at 10.6 per million doses.\n\nCDC officials also said that among those who develop TTS, the fatality rate was about 15%. The people who died deteriorated quickly after being admitted to the hospital, officials said.\n\nCDC officials said getting J&J’s vaccine was still superior to not getting vaccinated, but the balance between the benefits and risks for the messenger RNA vaccines from Pfizer-BioNTech and Moderna was superior to J&J’s. And the current supply of mRNA vaccines in the U.S. is adequate, unlike earlier in the year.\n\nA recommendation by the ACIP isn’t binding on vaccine providers or recipients, but it will carry significant weight because it has been rare for the committee to express a preference for one vaccine over another.\n\n\nSome committee members said that the J&J vaccine should remain available for people who aren’t able to take the mRNA vaccines.\n\nHealth officials say people with an allergy to ingredients in the mRNA vaccines, or who have had a severe allergic reaction to a dose of those vaccines, should not receive them.\n\nThe mRNA vaccines also carry a risk of causing heart-inflammation conditions including myocarditis, particularly among males under the age of 30. Yet health officials have said the benefits of preventing Covid-19 hospitalizations and deaths outweigh the myocarditis risk.\n\nPenny Heaton, global therapeutic area head of vaccines at J&J, told committee members that the company has been monitoring the safety of the vaccine, including the TTS risk. The vaccine is a life-saving tool, she said, and the company is supplying hundreds of millions of doses around the world.\n\nPartly because of the safety concerns, J&J’s single-dose vaccine has been used much less than the two-dose vaccines from Moderna and Pfizer with its partner BioNTech SE.\n\nAbout 16.1 million people in the U.S. have received J&J’s vaccine, according to the CDC. About 870,000 booster doses of J&J’s vaccine have been administered.\n\nMore than 113 million people have received two doses of the Pfizer-BioNTech vaccine and more than 72 million have received the two-dose Moderna vaccine in the U.S. More than 30 million booster doses of the Pfizer vaccine and 24 million Moderna booster doses have been administered in the U.S., according to the CDC.\n\nJ&J said Thursday it recently updated the fact sheet for its vaccine to say that it shouldn’t be administered to people who previously experienced TTS after receiving a prior dose of either the J&J vaccine or other vaccines with a similar adenovirus-based design.\n\nOther shots with a similar design include AstraZeneca PLC’s Covid-19 vaccine, which is available outside the U.S. but not in the U.S.\n\nThe recommendation threatens to affect support for J&J’s vaccine outside the U.S., including in countries struggling to increase their supplies of doses, just as J&J has begun shipping shots that Merck & Co. helped produce.\n\nThe CDC advisory committee members didn’t consider a recommendation against the use of J&J’s vaccine partly because such a move could undermine confidence in the vaccine in countries where people have better access to J&J’s vaccine over the mRNA vaccines.","news_type":1,"symbols_score_info":{"MRNA":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":2645,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691419155,"gmtCreate":1640226681816,"gmtModify":1640226681874,"author":{"id":"4087961992375920","authorId":"4087961992375920","name":"larrylim11","avatar":"https://static.tigerbbs.com/b349c02fde492311c83f02b5acc9f8dd","crmLevel":13,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087961992375920","authorIdStr":"4087961992375920"},"themes":[],"htmlText":"Wow..","listText":"Wow..","text":"Wow..","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691419155","repostId":"1141555850","repostType":4,"repost":{"id":"1141555850","kind":"news","pubTimestamp":1640226334,"share":"https://www.laohu8.com/m/news/1141555850?lang=&edition=full","pubTime":"2021-12-23 10:25","market":"us","language":"en","title":"Apple Stock: Will The Apple Car Be The Ultimate ‘Tesla Killer?’","url":"https://stock-news.laohu8.com/highlight/detail?id=1141555850","media":"TheStreet","summary":"Apple’s EV catalyst may help to boost returns in the long run. But in the near-term, it’s likely alr","content":"<p>Apple’s EV catalyst may help to boost returns in the long run. But in the near-term, it’s likely already priced into AAPL stock.</p>\n<p>Last week, we broke down Apple stock&nbsp;and its metaverse catalyst. Specifically, why the tech giant’s move into AR (augmented reality) and VR (virtual reality) hardware may give shares&nbsp;only a slight boost, at best.</p>\n<p>Now, let’s look at a potential catalyst that may be more of a needle-mover: the company’s Apple Car project. If its development and launch are successful, it’s not far-fetched to believe this fully autonomous electric vehicle (EV) could give top early-stage names in this space, like Lucid&nbsp;and Rivian, a run for their money.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ba4c0f33eddb42a2022a11999bb87bf2\" tg-width=\"1240\" tg-height=\"698\" width=\"100%\" height=\"auto\"><span>Figure 1: Apple Car prototype.</span></p>\n<p>Not only that, but the Apple Car may also have a shot of grabbing substantial market share from current leader Tesla. However, before putting in a buy order, let’s take a closer look at this catalyst, and its potential near and long-term impact on Apple shares.</p>\n<p><b>AAPL Stock and its Apple Car Catalyst</b></p>\n<p>Before diving in, here’s a brief overview of Apple and its EV project. For years, the company has been at work developing an electric vehicle.</p>\n<p>Before, it was designing both a limited self-driving vehicle, as well as a fully self-driving vehicle. Working on both projects at the same time made sense. It would enable it to launch an EV before fully autonomous capabilities became available.</p>\n<p>But now, with a new leader in charge of the project (Kevin Lynch),Apple is putting all its eggs in the fully autonomous basket. Speeding up its timeline, the company is targeting a 2025 release date for its fully autonomous EV.</p>\n<p>Given its track record, there are high expectations that Apple will meet this deadline and bring out a possible “Tesla killer” in less than four years. However, that’s not to say it’s a foregone conclusion.</p>\n<p><b>The Apple Maven’s Take</b></p>\n<p>Unlike its metaverse catalyst, the Apple Car may offer a lot more upside potential. As Morgan Stanley’s Katy Huberty argued back in November, its launch of a fully self-driving EV could ultimately&nbsp;double both its revenue and market cap.</p>\n<p>The sell-side analyst pointed to many factors to support her case — the company’s large customer base, for one. Also, there is Apple’s past success diving into uncharted territory. For example, the company was a latecomer to mobile communication devices when it launched the iPhone, but it currently holds&nbsp;23%&nbsp;of the market and growing.</p>\n<p>That said, while it has a strong chance of finding success, the Apple Car could still hiccup moving to the delivery stage. In fact, it’s already dealing with some hurdles right now, as seen from recent news of the project&nbsp;losing key engineers to rivals.</p>\n<p>On top of this, with AAPL stock&nbsp;already trading at a stretched forward earnings multiple, this catalyst may already be factored into its valuation. Ms. Huberty sees EV as something that could one day double the share price. Still, her current price target of $200 per share is less than 20% above the $170 per share that AAPL trades for today — suggesting that much of the Apple Car upside to the stock may not come until beyond 2022.</p>\n<p>Bottom line: the Apple Car may be something that helps the company and stock deliver solid long-term financial results and market gains, respectively. At the same time, it may fail to give shares a big jolt in the coming months.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple Stock: Will The Apple Car Be The Ultimate ‘Tesla Killer?’</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple Stock: Will The Apple Car Be The Ultimate ‘Tesla Killer?’\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-23 10:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/apple/other-products/apple-stock-will-the-apple-car-be-the-ultimate-tesla-killer><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Apple’s EV catalyst may help to boost returns in the long run. But in the near-term, it’s likely already priced into AAPL stock.\nLast week, we broke down Apple stock and its metaverse catalyst. ...</p>\n\n<a href=\"https://www.thestreet.com/apple/other-products/apple-stock-will-the-apple-car-be-the-ultimate-tesla-killer\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果","TSLA":"特斯拉"},"source_url":"https://www.thestreet.com/apple/other-products/apple-stock-will-the-apple-car-be-the-ultimate-tesla-killer","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1141555850","content_text":"Apple’s EV catalyst may help to boost returns in the long run. But in the near-term, it’s likely already priced into AAPL stock.\nLast week, we broke down Apple stock and its metaverse catalyst. Specifically, why the tech giant’s move into AR (augmented reality) and VR (virtual reality) hardware may give shares only a slight boost, at best.\nNow, let’s look at a potential catalyst that may be more of a needle-mover: the company’s Apple Car project. If its development and launch are successful, it’s not far-fetched to believe this fully autonomous electric vehicle (EV) could give top early-stage names in this space, like Lucid and Rivian, a run for their money.\nFigure 1: Apple Car prototype.\nNot only that, but the Apple Car may also have a shot of grabbing substantial market share from current leader Tesla. However, before putting in a buy order, let’s take a closer look at this catalyst, and its potential near and long-term impact on Apple shares.\nAAPL Stock and its Apple Car Catalyst\nBefore diving in, here’s a brief overview of Apple and its EV project. For years, the company has been at work developing an electric vehicle.\nBefore, it was designing both a limited self-driving vehicle, as well as a fully self-driving vehicle. Working on both projects at the same time made sense. It would enable it to launch an EV before fully autonomous capabilities became available.\nBut now, with a new leader in charge of the project (Kevin Lynch),Apple is putting all its eggs in the fully autonomous basket. Speeding up its timeline, the company is targeting a 2025 release date for its fully autonomous EV.\nGiven its track record, there are high expectations that Apple will meet this deadline and bring out a possible “Tesla killer” in less than four years. However, that’s not to say it’s a foregone conclusion.\nThe Apple Maven’s Take\nUnlike its metaverse catalyst, the Apple Car may offer a lot more upside potential. As Morgan Stanley’s Katy Huberty argued back in November, its launch of a fully self-driving EV could ultimately double both its revenue and market cap.\nThe sell-side analyst pointed to many factors to support her case — the company’s large customer base, for one. Also, there is Apple’s past success diving into uncharted territory. For example, the company was a latecomer to mobile communication devices when it launched the iPhone, but it currently holds 23% of the market and growing.\nThat said, while it has a strong chance of finding success, the Apple Car could still hiccup moving to the delivery stage. In fact, it’s already dealing with some hurdles right now, as seen from recent news of the project losing key engineers to rivals.\nOn top of this, with AAPL stock already trading at a stretched forward earnings multiple, this catalyst may already be factored into its valuation. Ms. Huberty sees EV as something that could one day double the share price. Still, her current price target of $200 per share is less than 20% above the $170 per share that AAPL trades for today — suggesting that much of the Apple Car upside to the stock may not come until beyond 2022.\nBottom line: the Apple Car may be something that helps the company and stock deliver solid long-term financial results and market gains, respectively. At the same time, it may fail to give shares a big jolt in the coming months.","news_type":1,"symbols_score_info":{"AAPL":0.9,"TSLA":0.9}},"isVote":1,"tweetType":1,"viewCount":1801,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691413731,"gmtCreate":1640226836214,"gmtModify":1640226836302,"author":{"id":"4087961992375920","authorId":"4087961992375920","name":"larrylim11","avatar":"https://static.tigerbbs.com/b349c02fde492311c83f02b5acc9f8dd","crmLevel":13,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087961992375920","authorIdStr":"4087961992375920"},"themes":[],"htmlText":"//<a href=\"https://laohu8.com/U/3576822652797861\">@iNights</a>: NiceWhoa","listText":"//<a href=\"https://laohu8.com/U/3576822652797861\">@iNights</a>: NiceWhoa","text":"//@iNights: NiceWhoa","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691413731","repostId":"1181809495","repostType":4,"repost":{"id":"1181809495","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640225885,"share":"https://www.laohu8.com/m/news/1181809495?lang=&edition=full","pubTime":"2021-12-23 10:18","market":"us","language":"en","title":"Moderna Is Dipping: What's Next?","url":"https://stock-news.laohu8.com/highlight/detail?id=1181809495","media":"Benzinga","summary":"Moderna Inc shares are trading lower Wednesday and are falling toward a support level.\nThe stock was","content":"<p><b>Moderna Inc</b>&nbsp;shares are trading lower Wednesday and are falling toward a support level.</p>\n<p>The stock was trending on social media sites throughout the day after the stock saw some movement.</p>\n<p>Moderna was down 6.26% at $251.36 at market close Wednesday.</p>\n<p><b>Moderna Daily Chart Analysis</b></p>\n<ul>\n <li>Shares dipped toward support in what traders call an ascending triangle pattern. Shares could see another bounce off the higher low support at some point in the future. Resistance is shown to be near the $460 level.</li>\n <li>The stock trades below the 50-day moving average (green) but above the 200-day moving average (blue). This indicates the stock is likely in a consolidation period, and the 50-day moving average may act as resistance while the 200-day moving average may hold as support.</li>\n <li>The Relative Strength Index (RSI) has been creeping lower the past few days and sits at 41. This shows that sellers are prevailing in the stock and are slightly overpowering buyers.</li>\n</ul>\n<p><img src=\"https://static.tigerbbs.com/62170d670dca987c7cbc558dd6666d0c\" tg-width=\"2400\" tg-height=\"1233\" width=\"100%\" height=\"auto\"></p>\n<p><b>What’s Next For Moderna?</b></p>\n<p>Moderna has seen a dip the past few days and is falling back toward the higher low trendline. If this area can see a bounce again the price may start to head toward resistance once again. Bulls are looking for higher lows to continue to form for the stock to keep the bullish trend. Bears are looking to see the stock fall below this trendline and for the price to start moving with lower highs.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Is Dipping: What's Next?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Is Dipping: What's Next?\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-12-23 10:18</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Moderna Inc</b>&nbsp;shares are trading lower Wednesday and are falling toward a support level.</p>\n<p>The stock was trending on social media sites throughout the day after the stock saw some movement.</p>\n<p>Moderna was down 6.26% at $251.36 at market close Wednesday.</p>\n<p><b>Moderna Daily Chart Analysis</b></p>\n<ul>\n <li>Shares dipped toward support in what traders call an ascending triangle pattern. Shares could see another bounce off the higher low support at some point in the future. Resistance is shown to be near the $460 level.</li>\n <li>The stock trades below the 50-day moving average (green) but above the 200-day moving average (blue). This indicates the stock is likely in a consolidation period, and the 50-day moving average may act as resistance while the 200-day moving average may hold as support.</li>\n <li>The Relative Strength Index (RSI) has been creeping lower the past few days and sits at 41. This shows that sellers are prevailing in the stock and are slightly overpowering buyers.</li>\n</ul>\n<p><img src=\"https://static.tigerbbs.com/62170d670dca987c7cbc558dd6666d0c\" tg-width=\"2400\" tg-height=\"1233\" width=\"100%\" height=\"auto\"></p>\n<p><b>What’s Next For Moderna?</b></p>\n<p>Moderna has seen a dip the past few days and is falling back toward the higher low trendline. If this area can see a bounce again the price may start to head toward resistance once again. Bulls are looking for higher lows to continue to form for the stock to keep the bullish trend. Bears are looking to see the stock fall below this trendline and for the price to start moving with lower highs.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1181809495","content_text":"Moderna Inc shares are trading lower Wednesday and are falling toward a support level.\nThe stock was trending on social media sites throughout the day after the stock saw some movement.\nModerna was down 6.26% at $251.36 at market close Wednesday.\nModerna Daily Chart Analysis\n\nShares dipped toward support in what traders call an ascending triangle pattern. Shares could see another bounce off the higher low support at some point in the future. Resistance is shown to be near the $460 level.\nThe stock trades below the 50-day moving average (green) but above the 200-day moving average (blue). This indicates the stock is likely in a consolidation period, and the 50-day moving average may act as resistance while the 200-day moving average may hold as support.\nThe Relative Strength Index (RSI) has been creeping lower the past few days and sits at 41. This shows that sellers are prevailing in the stock and are slightly overpowering buyers.\n\n\nWhat’s Next For Moderna?\nModerna has seen a dip the past few days and is falling back toward the higher low trendline. If this area can see a bounce again the price may start to head toward resistance once again. Bulls are looking for higher lows to continue to form for the stock to keep the bullish trend. Bears are looking to see the stock fall below this trendline and for the price to start moving with lower highs.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":1686,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691413302,"gmtCreate":1640226771801,"gmtModify":1640226771801,"author":{"id":"4087961992375920","authorId":"4087961992375920","name":"larrylim11","avatar":"https://static.tigerbbs.com/b349c02fde492311c83f02b5acc9f8dd","crmLevel":13,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087961992375920","authorIdStr":"4087961992375920"},"themes":[],"htmlText":"Yea..","listText":"Yea..","text":"Yea..","images":[{"img":"https://static.tigerbbs.com/e20070159fdd392e5a013b6c48806820","width":"1080","height":"1309"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691413302","isVote":1,"tweetType":1,"viewCount":1353,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":691292885,"gmtCreate":1640191003765,"gmtModify":1640191003765,"author":{"id":"4087961992375920","authorId":"4087961992375920","name":"larrylim11","avatar":"https://static.tigerbbs.com/b349c02fde492311c83f02b5acc9f8dd","crmLevel":13,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087961992375920","authorIdStr":"4087961992375920"},"themes":[],"htmlText":"Market will go back up!","listText":"Market will go back up!","text":"Market will go back up!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691292885","isVote":1,"tweetType":1,"viewCount":1407,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699862235,"gmtCreate":1639782488972,"gmtModify":1639782488972,"author":{"id":"4087961992375920","authorId":"4087961992375920","name":"larrylim11","avatar":"https://static.tigerbbs.com/b349c02fde492311c83f02b5acc9f8dd","crmLevel":13,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087961992375920","authorIdStr":"4087961992375920"},"themes":[],"htmlText":"Good stuff","listText":"Good stuff","text":"Good stuff","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/699862235","isVote":1,"tweetType":1,"viewCount":1350,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690550452,"gmtCreate":1639696288846,"gmtModify":1639696289837,"author":{"id":"4087961992375920","authorId":"4087961992375920","name":"larrylim11","avatar":"https://static.tigerbbs.com/b349c02fde492311c83f02b5acc9f8dd","crmLevel":13,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087961992375920","authorIdStr":"4087961992375920"},"themes":[],"htmlText":"Good stuff!","listText":"Good stuff!","text":"Good stuff!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690550452","repostId":"2192920942","repostType":4,"isVote":1,"tweetType":1,"viewCount":1407,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":842621749,"gmtCreate":1636171939170,"gmtModify":1636171939265,"author":{"id":"4087961992375920","authorId":"4087961992375920","name":"larrylim11","avatar":"https://static.tigerbbs.com/b349c02fde492311c83f02b5acc9f8dd","crmLevel":13,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087961992375920","authorIdStr":"4087961992375920"},"themes":[],"htmlText":"Whee!","listText":"Whee!","text":"Whee!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/842621749","repostId":"850756569","repostType":1,"repost":{"id":850756569,"gmtCreate":1634631211448,"gmtModify":1635853120757,"author":{"id":"36984908995200","authorId":"36984908995200","name":"小虎活动","avatar":"https://static.tigerbbs.com/9e396d03155923b283948d2dec9191f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"36984908995200","authorIdStr":"36984908995200"},"themes":[],"title":"[Halloween Game] Trade or Treat!","htmlText":"Hello, dear Tigers!&nbsp; Happy&nbsp;Halloween!&nbsp;🎃🎃🎃&nbsp;&nbsp; <a href=\"https://www.tigerbrokers.com.sg/activity/market/2021/halloween/?lang=en_US#/\" target=\"_blank\">Tap&nbsp;here&nbsp;to&nbsp;play the Halloween game,&nbsp;and&nbsp;you&nbsp;stand&nbsp;a&nbsp;chance&nbsp;to win various rewards!&nbsp;</a> Promotion Period: October 27, 2021 18:00 - November 9, 2021 18:00 (SGT) 1.&nbsp;How to Participate? All Tiger clients may collect points which can be used to redeem rewards by taking part in the Trade or Treating Game. All existing Tiger clients will have 2 game attempts. Clients can get more game attempts by completing different tasks, such as 'Invite a friend' or 'Share Halloween Game'.&nbsp; 2.&nbsp;How to collect points? Each player has 30 seconds to catch falling candies while av","listText":"Hello, dear Tigers!&nbsp; Happy&nbsp;Halloween!&nbsp;🎃🎃🎃&nbsp;&nbsp; <a href=\"https://www.tigerbrokers.com.sg/activity/market/2021/halloween/?lang=en_US#/\" target=\"_blank\">Tap&nbsp;here&nbsp;to&nbsp;play the Halloween game,&nbsp;and&nbsp;you&nbsp;stand&nbsp;a&nbsp;chance&nbsp;to win various rewards!&nbsp;</a> Promotion Period: October 27, 2021 18:00 - November 9, 2021 18:00 (SGT) 1.&nbsp;How to Participate? All Tiger clients may collect points which can be used to redeem rewards by taking part in the Trade or Treating Game. All existing Tiger clients will have 2 game attempts. Clients can get more game attempts by completing different tasks, such as 'Invite a friend' or 'Share Halloween Game'.&nbsp; 2.&nbsp;How to collect points? Each player has 30 seconds to catch falling candies while av","text":"Hello, dear Tigers! Happy Halloween! 🎃🎃🎃 Tap here to play the Halloween game, and you stand a chance to win various rewards! Promotion Period: October 27, 2021 18:00 - November 9, 2021 18:00 (SGT) 1. How to Participate? All Tiger clients may collect points which can be used to redeem rewards by taking part in the Trade or Treating Game. All existing Tiger clients will have 2 game attempts. Clients can get more game attempts by completing different tasks, such as 'Invite a friend' or 'Share Halloween Game'. 2. How to collect points? Each player has 30 seconds to catch falling candies while av","images":[],"top":1,"highlighted":2,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/850756569","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":1411,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":848103890,"gmtCreate":1635980926483,"gmtModify":1635980926610,"author":{"id":"4087961992375920","authorId":"4087961992375920","name":"larrylim11","avatar":"https://static.tigerbbs.com/b349c02fde492311c83f02b5acc9f8dd","crmLevel":13,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087961992375920","authorIdStr":"4087961992375920"},"themes":[],"htmlText":"Yes!","listText":"Yes!","text":"Yes!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/848103890","repostId":"850756569","repostType":1,"repost":{"id":850756569,"gmtCreate":1634631211448,"gmtModify":1635853120757,"author":{"id":"36984908995200","authorId":"36984908995200","name":"小虎活动","avatar":"https://static.tigerbbs.com/9e396d03155923b283948d2dec9191f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"36984908995200","authorIdStr":"36984908995200"},"themes":[],"title":"[Halloween Game] Trade or Treat!","htmlText":"Hello, dear Tigers!&nbsp; Happy&nbsp;Halloween!&nbsp;🎃🎃🎃&nbsp;&nbsp; <a href=\"https://www.tigerbrokers.com.sg/activity/market/2021/halloween/?lang=en_US#/\" target=\"_blank\">Tap&nbsp;here&nbsp;to&nbsp;play the Halloween game,&nbsp;and&nbsp;you&nbsp;stand&nbsp;a&nbsp;chance&nbsp;to win various rewards!&nbsp;</a> Promotion Period: October 27, 2021 18:00 - November 9, 2021 18:00 (SGT) 1.&nbsp;How to Participate? All Tiger clients may collect points which can be used to redeem rewards by taking part in the Trade or Treating Game. All existing Tiger clients will have 2 game attempts. Clients can get more game attempts by completing different tasks, such as 'Invite a friend' or 'Share Halloween Game'.&nbsp; 2.&nbsp;How to collect points? Each player has 30 seconds to catch falling candies while av","listText":"Hello, dear Tigers!&nbsp; Happy&nbsp;Halloween!&nbsp;🎃🎃🎃&nbsp;&nbsp; <a href=\"https://www.tigerbrokers.com.sg/activity/market/2021/halloween/?lang=en_US#/\" target=\"_blank\">Tap&nbsp;here&nbsp;to&nbsp;play the Halloween game,&nbsp;and&nbsp;you&nbsp;stand&nbsp;a&nbsp;chance&nbsp;to win various rewards!&nbsp;</a> Promotion Period: October 27, 2021 18:00 - November 9, 2021 18:00 (SGT) 1.&nbsp;How to Participate? All Tiger clients may collect points which can be used to redeem rewards by taking part in the Trade or Treating Game. All existing Tiger clients will have 2 game attempts. Clients can get more game attempts by completing different tasks, such as 'Invite a friend' or 'Share Halloween Game'.&nbsp; 2.&nbsp;How to collect points? Each player has 30 seconds to catch falling candies while av","text":"Hello, dear Tigers! Happy Halloween! 🎃🎃🎃 Tap here to play the Halloween game, and you stand a chance to win various rewards! Promotion Period: October 27, 2021 18:00 - November 9, 2021 18:00 (SGT) 1. How to Participate? All Tiger clients may collect points which can be used to redeem rewards by taking part in the Trade or Treating Game. All existing Tiger clients will have 2 game attempts. Clients can get more game attempts by completing different tasks, such as 'Invite a friend' or 'Share Halloween Game'. 2. How to collect points? Each player has 30 seconds to catch falling candies while av","images":[],"top":1,"highlighted":2,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/850756569","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":452,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":841123231,"gmtCreate":1635897114472,"gmtModify":1635897114472,"author":{"id":"4087961992375920","authorId":"4087961992375920","name":"larrylim11","avatar":"https://static.tigerbbs.com/b349c02fde492311c83f02b5acc9f8dd","crmLevel":13,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087961992375920","authorIdStr":"4087961992375920"},"themes":[],"htmlText":"Woo hoo!","listText":"Woo hoo!","text":"Woo hoo!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/841123231","repostId":"850756569","repostType":1,"repost":{"id":850756569,"gmtCreate":1634631211448,"gmtModify":1635853120757,"author":{"id":"36984908995200","authorId":"36984908995200","name":"小虎活动","avatar":"https://static.tigerbbs.com/9e396d03155923b283948d2dec9191f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"36984908995200","authorIdStr":"36984908995200"},"themes":[],"title":"[Halloween Game] Trade or Treat!","htmlText":"Hello, dear Tigers!&nbsp; Happy&nbsp;Halloween!&nbsp;🎃🎃🎃&nbsp;&nbsp; <a href=\"https://www.tigerbrokers.com.sg/activity/market/2021/halloween/?lang=en_US#/\" target=\"_blank\">Tap&nbsp;here&nbsp;to&nbsp;play the Halloween game,&nbsp;and&nbsp;you&nbsp;stand&nbsp;a&nbsp;chance&nbsp;to win various rewards!&nbsp;</a> Promotion Period: October 27, 2021 18:00 - November 9, 2021 18:00 (SGT) 1.&nbsp;How to Participate? All Tiger clients may collect points which can be used to redeem rewards by taking part in the Trade or Treating Game. All existing Tiger clients will have 2 game attempts. Clients can get more game attempts by completing different tasks, such as 'Invite a friend' or 'Share Halloween Game'.&nbsp; 2.&nbsp;How to collect points? Each player has 30 seconds to catch falling candies while av","listText":"Hello, dear Tigers!&nbsp; Happy&nbsp;Halloween!&nbsp;🎃🎃🎃&nbsp;&nbsp; <a href=\"https://www.tigerbrokers.com.sg/activity/market/2021/halloween/?lang=en_US#/\" target=\"_blank\">Tap&nbsp;here&nbsp;to&nbsp;play the Halloween game,&nbsp;and&nbsp;you&nbsp;stand&nbsp;a&nbsp;chance&nbsp;to win various rewards!&nbsp;</a> Promotion Period: October 27, 2021 18:00 - November 9, 2021 18:00 (SGT) 1.&nbsp;How to Participate? All Tiger clients may collect points which can be used to redeem rewards by taking part in the Trade or Treating Game. All existing Tiger clients will have 2 game attempts. Clients can get more game attempts by completing different tasks, such as 'Invite a friend' or 'Share Halloween Game'.&nbsp; 2.&nbsp;How to collect points? Each player has 30 seconds to catch falling candies while av","text":"Hello, dear Tigers! Happy Halloween! 🎃🎃🎃 Tap here to play the Halloween game, and you stand a chance to win various rewards! Promotion Period: October 27, 2021 18:00 - November 9, 2021 18:00 (SGT) 1. How to Participate? All Tiger clients may collect points which can be used to redeem rewards by taking part in the Trade or Treating Game. All existing Tiger clients will have 2 game attempts. Clients can get more game attempts by completing different tasks, such as 'Invite a friend' or 'Share Halloween Game'. 2. How to collect points? Each player has 30 seconds to catch falling candies while av","images":[],"top":1,"highlighted":2,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/850756569","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":518,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":144370844,"gmtCreate":1626270128588,"gmtModify":1633928446212,"author":{"id":"4087961992375920","authorId":"4087961992375920","name":"larrylim11","avatar":"https://static.tigerbbs.com/b349c02fde492311c83f02b5acc9f8dd","crmLevel":13,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087961992375920","authorIdStr":"4087961992375920"},"themes":[],"htmlText":"Good stuff","listText":"Good stuff","text":"Good stuff","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/144370844","repostId":"1158673076","repostType":4,"isVote":1,"tweetType":1,"viewCount":147,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":143020380,"gmtCreate":1625753028240,"gmtModify":1633937686390,"author":{"id":"4087961992375920","authorId":"4087961992375920","name":"larrylim11","avatar":"https://static.tigerbbs.com/b349c02fde492311c83f02b5acc9f8dd","crmLevel":13,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087961992375920","authorIdStr":"4087961992375920"},"themes":[],"htmlText":"Oh no..","listText":"Oh no..","text":"Oh no..","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/143020380","repostId":"1195364777","repostType":4,"isVote":1,"tweetType":1,"viewCount":150,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":159252598,"gmtCreate":1624971958014,"gmtModify":1633946386466,"author":{"id":"4087961992375920","authorId":"4087961992375920","name":"larrylim11","avatar":"https://static.tigerbbs.com/b349c02fde492311c83f02b5acc9f8dd","crmLevel":13,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087961992375920","authorIdStr":"4087961992375920"},"themes":[],"htmlText":"Good stuff!","listText":"Good stuff!","text":"Good stuff!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/159252598","repostId":"1100563900","repostType":2,"isVote":1,"tweetType":1,"viewCount":210,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}